Paul Peter Tak, Candel Therapeutics CEO

Us­ing her­pes virus vec­tors, Paul Pe­ter Tak and Carl June team up to solve the CAR-T sol­id tu­mor chal­lenge

Paul Pe­ter Tak’s on­colyt­ic virus start­up is jump­ing head-first in­to a new part­ner­ship, look­ing to tack­le sol­id tu­mor CAR-Ts.

Can­del Ther­a­peu­tics is join­ing forces with Carl June’s lab at the Uni­ver­si­ty of Penn­syl­va­nia to see if the her­pes virus can boost the ef­fec­tive­ness of CAR-T ther­a­pies in sol­id tu­mors, the biotech an­nounced Wednes­day morn­ing. No fi­nan­cial terms were dis­closed, and both par­ties will re­tain their re­spec­tive in­tel­lec­tu­al prop­er­ty rights.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.